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Abstract: 
 
Microvesicles are members of the family of extracellular vesicles shed from the plasma 
membrane of activated or apoptotic cells. Microvesicles were initially characterized by 
their pro-     ǲǳǤ There is mounting 
evidence revealing a role for microvesicles in intercellular communication, with 
particular relevance to hemostasis and vascular biology. Coupled with this, the potential 
of microvesicles as meaningful biomarkers is under intense investigation. This review 
will summarize the current knowledge on the mechanisms of formation and 
composition of microvesicles of endothelial, platelet, red blood cell and leukocyte origin. 
This paper will also review and discuss the different methods used for their analysis and 
quantification, will underline the potential biological roles of these vesicles with respect 
to vascular homeostasis and thrombosis and define important themes for future 
research.  
 
,QWURGXFWLRQ 
Microvesicles (MVs) belong to the family of extracellular vesicles (EVs), including 
exosomes and apoptotic bodies, shed from activated or apoptotic cells. These 
extracellular vesicles are distinguished on the basis of their subcellular origin, their size, 
their content and the mechanism leading to their formation.   
MVs were initially characterized by their pro-coagulant activity. Seminal work 
demonstrated that platelet-deprived plasma could support coagulation and that its 
clotting property was abrogated by high-speed centrifugation (1, 2). Wolf identified the 
phospholipid-containing material, derived from platelets and capable of supporting 
coagulation, as platelet dust, subsequently called microparticles (2, 3). For these 
historical reasons, the term microparticle is the most commonly employed to refer to 
extracellular vesicles generated from platelets in the fields of hemostasis and 
thrombosis. The term microvesicle, however, is utilized within this review for 
consistency, and refers to extracellular vesicles produced by cytoplasmic membrane 
blebbing and shedding (2, 4), and is distinguishable from the vesicles stored in 
multivesicular bodies or alpha-granules, called exosomes (5, 6). 
Today, MVs are interesting biomarkers with potential prognosis value as their content 
(proteins, active lipids, miRNA) (7, 8) varies with the inducer that initiated their 
shedding and with the severity of the disease (9-14). In addition, MVs emerge as new 
regulators of cellular crosstalk, in particular in vascular biology. 
The present Position Paper, rather than systematically reviewing the literature, will 
critically summarize the current knowledge on the mechanisms of formation of MVs, 
their cellular origin, their composition, and the methods used for their analysis and 
quantification; potential pitfalls in MV quantification and functional effects will be 
discussed. In addition, this review will enlighten the potential biological roles of these 
vesicles with respect to vascular homeostasis and thrombosis.  
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0LFURYHVLFOHIRUPDWLRQ 
2.1. Phospholipid transbilayer and phosphatidylserine exposure 
The asymmetry of phospholipid distribution across the plasma membrane is a common 
feature of resting eukaryotic cells. Conversely, loss of asymmetry is a driving force for 
plasma membrane remodelling, i.e. lipid motion and membrane deformation. 
Modification of the monolayer content in diffusible molecules alters lipid packing and 
causes membrane instability, regulated by sphingomyelinases that produce diffusible 
ceramides and prompt PS and phosphatidylcholine translocation and membrane 
budding (15-17). Whether ceramides and inner-leaflet interacting annexins also prompt 
agonist-driven MV release is unknown (18, 19). Other membrane adaptors, like arrestin-
domain-containing-protein 1, appear to mediate the release of small plasma membrane 
vesicles of undetermined composition (20). The recently identified crowding effect of 
integral asymmetric proteins with large ectodomains and smaller intracellular ones also 
favours membrane bending in liposomes (21). Whether integrins that are highly 
distributed in platelets, endothelial cells or leukocytes take part in crowding-driven 
budding effects remains unknown (22, 23). 
In resting cells, spontaneous phospholipid transbilayer transport is very slow (1 
lipid/24h) (15, 24). Asymmetry is the result of the opposing activities of ATP-dependent 
phospholipid transporters governing inward (flippases) or outward (floppases) 
translocation and of non-specific bi-directional ATP-independent lipid transporters 
(scramblases). During agonist-induced calcium cell stimulation, PS exposure results 
from (i) calcium-dependent inhibition of flippase and (ii) its rapid translocation exerted 
by floppase(s) and/or scramblase(s) (25-27). The calcium-dependent proteolysis of the 
cytoskeleton leads to an eventual transient imbalance in phospholipid density between 
the two leaflets driven by the swift PS egress and a lower phosphatidylcholine and 
sphingomyeline reverse transport (28, 29). This triggers local instability of the plasma 
membrane and shedding of MVs that are released upon raft clustering (30-32). The 
calcium-dependent channel TMEM16F (ANO6), an anoctamin, has recently been 
demonstrated to play a pivotal role in calcium-induced phospholipid scrambling in the 
release of MVs exposing PS (25, 33-36).  Interestingly, TMEM16F is mutated in Scott 
Syndrome, a rare human inherited bleeding disorder caused by defective platelet PS 
membrane exposure and MV shedding also evidenced in red cells and leukocytes (34, 
37-40). 
The existing data in isolated cells support the concept of MVs exposing PS as a 
consequence of membrane randomization. PS translocation and MV release are both 
defective in response to procoagulant agonists in Scott syndrome, suggesting that PS 
exposure is a prerequisite to MV shedding (41, 42). Moreover, annexin-5, a high affinity 
PS ligand, inhibits MV release from stimulated cells (43). Finally, PS exposure and PS-
positive MV shedding show similar time and concentration dependence whilst agonists 
induce distinct MV protein signatures (8, 44-47). 
Important proportions of MVs lacking externalized PS, but expressing cellular markers, 
have been reported in cell supernatants and in plasma (4, 46, 48-50). However little is 
known about the nature and mechanisms of these vesicles. These observations may 
result from the heterogeneous nature of MVs. They may also be the result of altered 
membrane fluidity by exogenous proteins in addition to differences in detection 
thresholds (15, 43, 51). However, one cannot exclude artefacts in MV 
assessment/labelling, including contamination with other extracellular vesicles or 
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proteins, absence of calcium that dampen PS detection (annexin, lactadherin, Del-1) (43, 
52, 53) or prompt fusion with other vesicles or proteins (54-57). This does not rule out 
the existence of these MVs derived from an, as yet, undetermined mechanism of 
membrane release. 
The use of annexin V positivity to identify MV populations in flow cytometry analysis is 
widespread. However, annexin V labeling could be skewed due to the presence of 
phosphatidylserine on lipoproteins(58). Furthermore, the possibility of the existence of 
PS negative MVs may mean that a proportion of MVs are excluded from analysis should 
this criteria be applied. This population may indeed differ in proportion and function 
depending on the parent cell. The possibility remains that by excluding PS negative MVs 
(or those MVs that bind annexin V below the detection limit of flow cytometers) an 
important sub-population of MVs will remain ill-described and unstudied. In addition, it 
is well known that apoptotic bodies have exposed PS on their surface and caution must 
be taken when analysing PS positive MV populations to ensure there is no 
contamination with vesicles released via apoptosis. 
2.2 Cytoskeleton reorganization and MV formation 
The cytoskeleton and hydrostatic pressure equilibrate plasma membrane tension 
whereas curvature instability of the bilayer drives membrane shape fluctuations and Ǥ  ǡȽȾ ? -mediated destabilization of the actin cytoskeleton 
promotes the release of procoagulant MVs, confirming that cytoskeleton integrity is 
critical for membrane asymmetry (59). The role of cytoskeleton reorganization in MV 
shedding was ascertained by inhibition of calcium-dependent proteases or actin 
depolymerisation that abolish MV release in stimulated platelets and megakaryocytes 
(60, 61) (Figure 1).  Depending on the cell lineage, agonist-induced Ca2+ influx prompts 
the protease activity of caspases and/or calpains that cleave typical cytoskeleton 
proteins like filamin,  gelsolin, talin and myosin (60, 62). Calpains are critical for platelet 
or neutrophil shedding, caspases for MV generation in vascular cells under apoptotic 
and non-apoptotic conditions (30, 63). Caspases mainly act through Rho kinase-
dependent phosphorylation of the myosin light chain kinases (MLCK) (64-67), although 
Rho-kinase dependent endothelial MV formation can be independent of caspase 
activation (68). The release of neutrophil MVs is caspase-8 dependent and requires 
phosphokinase A and MLCK (69). In tumor cells, the RhoȂdriven cytoskeleton 
reorganization and its relevance to exaggerated MV shedding identifies the pivotal role 
of small GTP-binding proteins, such as Rab22A (70) or ARF6 (71). Finally, caspase-3 
directly triggers Xkr8, a putative scramblase or caspase transducer that promotes PS 
exposure in the membrane of apoptotic cells (72). 
 
0LFURYHVLFOHVPHWKRGRORJ\XSGDWH 
3.1 Detection of MV 
Methodologies to study MVs can be classified based on detection of single or multiple 
MVs. The most common methods to study single MVs are flow cytometry, tunable 
resistive pulse sensing (TRPS), and nanoparticle tracking analysis (NTA). Methods to 
study multiple MVs include immunocapture-assays, functional assays, and hybrid assays Ǥǡǲǳ
offer potential for high-throughput processing of clinical samples, may be sensitive 
enough to take the functional contribution of small MVs into account, and can be more 
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cost-effective and user-friendly than single vesicle detection-based methods. However, 
single MV detection methods offer information on size or cellular origin of single MV, 
and thus may be more suitable to determine the presence of rare subtypes of MVs in a 
mixed population.  
More recently, surface plasmon resonance imaging combined with protein microarray 
technology has been applied to MVs (73). An array of antibodies are printed on a gold 
chip, and antibody captured MVs induce a change in refractive index. Potentially, surface 
plasmon resonance imaging may be useful for parallel and multiple analysis of MVs in 
clinical body fluids (74). 
3.2 Pitfalls in MV measurements 
Among the single particle-based method, flow cytometry remains the most commonly 
used technique with the highest potential to determine the cellular origin of single MV 
(75-77). Over the past few years, significant improvements have been made regarding 
the sensitivity of flow cytometry to detect single vesicles with a diameter of < 300 nm, 
which have further established this methodology as the most promising tool for routine 
enumeration of MV subsets (78-80). Because a method has been developed to derive 
information on absolute size (diameter) and refractive index of single MVs and similar-
sized particles from flow cytometry light scatter signals, the comparison of absolute 
measurement results on MV between instruments and institutes may come within reach 
(81, 82). However, it is important to note that accurate detection of MVs by flow 
cytometry is still a challenge, in particular for circulating MV analysis (56, 83-85).  
NTA measures the Brownian motion of single particles in a laser beam (86) and is a 
valuable tool for the measurement of size distribution of MVs. The light scattered from 
single particles is visualized by microscopy, and the movement of single particles is 
monitored and recorded in time. Although NTA detects particles with a diameter < 100 
nm, the resolution is low (75). The main limitation of NTA, however, is the inability to 
distinguish MV from similar-sized particles in suspension (i.e. debris). The ability to use 
the fluorescent mode offers the opportunity to specifically identify MVs. An alternative 
method, TRPS, is based on impedance to monitor individual MVs with a diameter of 80Ȃ
1,000 nm or more, as they move through tunable nanopores (87). Particles passing the 
pore generate a change in the electric resistance, thus providing information on 
diameter, surface charge, concentration, and zeta potential of single particles. The major 
disadvantage of TRPS is that it cannot distinguish between MVs and similar sized 
particles such as chylomicrons or protein aggregates.  
Each of the above methods has advantages and disadvantages. Therefore, to confirm the 
presence of MVs, ISEV recommends the use of a second independent method (88)[also 
see Section 9]. As an independent method, often transmission electron microscopy is 
used, because this technique has a high resolution and can distinguish intact MVs from 
non-MVs at the level of a single particle.   
3.3 Standardization of MV measurements 
Standardization is mandatory to allow evaluation of the true clinical relevance of MV at a 
multicenter level, and should be accompanied by continuous improvement of methods. 
Flow cytometry is the first method to benefit from standardization efforts coordinated 
by the ISTH Standardization Committee on Vascular Biology. Thus, several bead-based 
comparison studies have been performed to standardize light scatter gates for MV 
selection between instruments (76, 89). At present, additional standardization 
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strategies are being tested based on either absolute vesicle size approximation or 
fluorescence (90). In 2015, a collaborative workshop was initiated to standardize MV 
detection by flow cytometry (www.evflowcytometry.org). In this workshop the 
knowledge from three international societies is combined: International Society on 
Extracellular Vesicles provides knowledge on vesicles, International Society on 
Advancement of Cytometry provides knowledge on detection of MV by flow cytometry, 
and the International Society on Thrombosis and Haemostasis contributes with 
expertise on blood collection, handling and storage. Similarly, attempts are on-going to 
standardize TRPS measurements and coagulation. 	ȋȌǲǳǤǡ
now an urgent need for developing novel guidelines regarding collection, handling and 
storage, as required for reliable biorepositories. Recently, a start has been made in 
developing such guidelines for human blood, urine and saliva using sensitive MV 
detection methods ((91); www.metves.eu), but more research is clearly required. 
Furthermore, labelling protocols for flow cytometry require updates and improvements, 
and standards and validation protocols need to be developed. Finally, training and 
education are now being developed, such as the online course developed by ISEV on the ǲ   ǳǡ    
(https://www.coursera.org/learn/extracellular-vesicles). In addition, the ISTH 
Academy has recorded two webinars on MVs. Both courses include up-to-date 
information on isolation and detection of MVs.  
 
3.4 MV isolation and pitfalls in testing their functional effects 
One of the most important considerations when isolating MVs from blood is the 
presence of contaminating platelets. When comparative studies are performed, sample 
preparation must be identical in order that any artefact is present in all samples (91). In 
most studies, MVs are isolated and/or concentrated using protocols involving either 
initial low or intermediate multiple centrifugations, combined with ultracentrifugation, 
density gradient centrifugation, or combinations thereof. These MV populations are 
impure and contaminated by plasma or serum proteins hence affecting the outcome of 
functional or Ȃomics measurements (Table 1). To overcome these limitations, size 
exclusion chromatography has been adopted recently by many investigators to separate 
MVs from soluble proteins in cell preparation ((92); www.metves.eu), thereby 
facilitating for example detection of MVs by electron microscopy as well as Ȃomics 
studies of EVs. More quantitative information is clearly needed about the extent of MV 
recovery for each isolation method (93). 
Several questions may arise when testing MV functional effects either in vitro or in vivo. 
First, the choice of MV concentrations should be of physiological or pathological 
relevance. Surprisingly, few studies evaluate the effects of more than one concentration 
of MVs, although previous reports point out the paradoxical effects of different MV 
concentrations (94). Second, the experimental design should include robust controls, 
including the supernatant above the isolated MV pellet. Control experiments using 
saline-buffered solutions may be also an additional control. When cytokines or 
inhibitors are used to trigger MV release in vitro, caution should be taken to remove 
these compounds from the enriched vesicle preparation, for example by dialysis or size 
exclusion chromatograph, to avoid experimental bias. The presence of large numbers of 
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MVs and exosomes in serum used for culture experiments should also be taken into 
account. Similarly, presence of lipoproteins, hormones and other mediators in plasma 
should also be taken into account when designing adequate control experiments for 
testing functional effects of circulating MVs. Finally, in vivo effects of MV of human origin 
need to be tested in suitable animal models in order to avoid immune reaction to human 
biological material that would mask MV functional effect.   
 
0LFURYHVLFOHVDVUHJXODWRUVRIFHOOFRPPXQLFDWLRQ 
In 1996, Raposo et al. demonstrated that EVs could be transferred between cells (95). 
This concept is based on the observation that EVs released from a given cell type 
interact through specific receptor ligand with other cells, leading to trigger cell 
stimulation directly or by transferring the surface receptors (96). Since then, numerous 
studies confirmed that EVs are an important mode of intracellular communication and 
cargo delivery between cells, including platelets, endothelial cells, and monocytes. Hence, 
it is now recognized that EVs are an integral part of the intercellular microenvironment 
and act as regulators of cell-to-cell communication (Figure 2). 
Ratajczak et al. proposed that MV-mediated cell-to-cell communication emerged very 
early during the evolution as one of the first communication mechanisms (97).  The first 
evidence for MV-mediated protein transfer was observed by Barry et al. where bioactive 
lipids were functionally transferred via platelet MVs to endothelial cells leading to 
specific biological effects (98). Another example is the transfer of arachidonic acid 
between activated and resting platelets that results in the modulation of their 
procoagulant responses (99). 
Since then, significant progress has been made in the field of MV transfer. However, the 
study of MV release and uptake within in vitro and in vivo settings remains challenging, 
as there are no reliable detection methods to discriminate cells that uptake EVs from 
cells that do not. Recently, a promising novel tool using Cre-loxP system has been 
developed to directly identify the fluorescently marked Cre-reporter cells that take up 
EVs released from Cre recombinaseȂexpressing cells (100).  
4.1 MV uptake and clearance 
The mechanisms controlling vesicle uptake and internalization are still a matter of 
debate. Various mechanisms have been proposed, including endocytosis (101), 
phagocytosis (102) and plasma or endosomal membrane fusion (103). Their molecular 
mechanisms have been validated using antibodies to test the role of specific ligands or 
receptors, and chemical inhibitors to block specific uptake pathways. A recent study has 
shown specific differences between exosomes and MVs for transferring genetic 
information (104). In particular, MVs, but not exosomes, can functionally transfer loaded 
reporter molecules to recipient cells. These results have significant implications for the 
understanding of EVs role in cellular communication and further development of EVs as 
vehicles for macromolecule delivery. 
Several studies have also demonstrated rapid clearance of MVs of different cellular 
origin from the circulation, mainly by liver and spleen phagocytes (55, 105-107). 
However, there is no definitive mechanism regarding the cell types involved in uptake 
and the potential consequences of such uptake. The presence of externalized PS is of 
vital importance for effective uptake through glycoproteins Del-1 or lactadherin 
bridging ǯ PS and cellular integrins on endothelial cells and macrophages, 
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respectively (106, 108, 109). The receptor tyrosine kinases Tyro3, Axl and Mer and their 
ligands protein S and Gas6 are also involved in the PS-dependent uptake of MV by 
macrophages and endothelial cells (110). In addition, lipid raftȂmediated endocytosis 
contributes to MV internalisation in human brain endothelial cells, but not in those 
originating from human umbilical vein (109, 111). MV uptake also depends upon how 
they are produced. For instance, stimulation of human aortic endothelial cells with 
tumor necrosis factor D (TNF-Ƚ) leads to the formation of two populations of MVs, with 
distinct miRNA content (112). MVs rich in miRNAs are taken up much faster than the 
other MV population, suggesting that endothelial cells could differentially recognize MVs 
generated upon different molecular cues.  
4.2 Cargo transfer 
MVs influence behaviour of target cells in multiple ways: by directly activating cell 
surface receptors via protein and bioactive ligands, by transfer of cell surface receptors 
or delivery, including transcription factors, mRNA and non-coding RNA. The bioactive 
ligands exposed on the MV surface are responsible for several important regulatory 
processes; for instance, direct stimulation of endothelial cells with MV- associated CD40 
ligand (CD40L) stimulates angiogenic responses in vivo (113). Moreover, MVs can 
transfer the adhesion molecule CD41 (Integrin alpha-IIb) from platelets to endothelial 
cells, conferring the latter pro-adhesive properties (114). Transfer of the chemokine 
CCL5 (RANTES) exposed on platelet MVs to target endothelial cells by GPIIb/IIIa and 
JAM-A dependent mechanisms contributes to monocyte recruitment (115). Furthermore, 
intercellular adhesion molecule-1 (ICAM-1) is transferred, by a PS-dependent 
mechanism, from MVs isolated from atherosclerotic human plaques and functionally 
integrated into endothelial cells following membrane fusion, resulting in increased 
monocyte adhesion and transmigration (116).  
The presence of functional mRNA in EVs was first described in 2006 for murine stem 
cell-derived vesicles (117). EVs, however, could also transport mRNA fragments (118), 
long non-coding RNA (119), miRNA (120, 121), ribosomal RNA (rRNA) (119)  and 
fragments of tRNA-, vault- and Y-RNA (122). This concept that non-coding RNA, and 
specifically miRNA, are transported into extracellular spaces, together with the evidence 
that exchange of miRNAs between cells can be accomplished through EVs, led to a 
revolutionary hypothesis of the existence of a miRNA vesicle-mediated communication 
system. Embedding of miRNAs in EVs could explain their resistance to nucleases when 
released outside the cell (123, 124). A large fraction of miRNAs exported by cells also 
associates with the Argonaute (Ago) protein family (125). Some studies report absence 
of RISC complex proteins (including Ago2) in the exosomes sub-group of EVs (126), 
whereas others report presence of Ago2 protein (127). In this regard, RISC proteins in 
EVs could process precursor microRNAs (pre-miRNAs) into mature miRNAs, inducing 
the cell-independent microRNA biogenesis (128). This is an exiting novel area of 
research that requires caution due to numerous potential pitfalls in the interpretation of 
the data as changes in miRNA content may not result in functional changes in the target 
cell.   
Endothelial EVs can stimulate repair by functionally influencing endothelial target cells. 
For instance, endothelial MVs and apoptotic bodies can transfer functional miR-126 to 
target endothelium to promote CXCL12-mediated angiogenic cell recruitment for 
atheroprotection or re-endothelialisation after endothelial injury in mice by stimulating 
endothelial migration and proliferation, due to downregulation of RGS16 and SPRED1, 
respectively (121, 129). Endothelial p75 neurotrophin receptor activates the NF-ɈB 
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signalling, inducing miR-503 transcription and the shedding of endothelial MVs by 
triggering the expression of Rho kinase (130). Intriguingly, miR-503-containing 
endothelial MVs are taken up by pericytes in vivo leading to, downregulation of miR-503 
target genes, EFNB2 and vascular endothelial growth factor A (VEGFA), and increased 
vessel permeability (130). Furthermore, miR-143 and miR-145 packaged in endothelial 
EVs released under shear stress are taken up by smooth muscle cells, where they 
downregulate target genes, inducing atheroprotective effects (131). Finally, circulating 
MVs from patients with coronary artery disease are deficient in Del-1, a glycoprotein 
mediating their endothelial uptake. Ex vivo, this led to a reduced uptake of MV-
associated miRNAs (miR-17, miR-19a, miR-21, miR-92a, miR-146a, miR-222, and miR-
223) in recipient cultured endothelial cells (132). 
 
(QGRWKHOLDOPLFURYHVLFOHV 
The suggestion that endothelial MVs are causative agents in vascular pathology has 
arisen from their numerical increase in a range of diseases that have been extensively 
reviewed (133-135).  Endothelial derived MVs carry endothelial proteins such as 
adhesion molecules (VE-cadherin, platelet endothelial cell adhesion molecule 1, 
intercellular adhesion molecule 1 (ICAM-1), E-selectin, Dv integrin), growth factors 
(Endoglin, S-Endo 1 (CD146), VEGF receptor 2 (VEGF-R2, hemostatic molecules (von 
Willebrand factor, TF, TF pathway inhibitor (TFPI), tissue plasminogen activator, 
plasminogen activator inhibitor 1, endothelial protein C receptor (EPCR)) or active 
components (Endothelial NO synthase, urokinase type plasminogen activator) (136). 
They have also been reported in human and murine plasma (137, 138), vitreous fluid 
(139) and in inflammatory lesions such as the atherosclerotic plaque or ischemic tissues 
(140) (Table 2). The composition of endothelial MVs depends upon the stimulus 
triggering their biogenesis, and their components originate from the plasma membrane, 
the cytosolic fraction, the cytoskeleton or from mitochondria (8). Elevated numbers of 
endothelial MVs were first reported in 1999 in disease populations, and were thus 
considered as potential diagnostic and prognostic biomarkers (137) (Table 2).  
5.1 Regulation of endothelial MV formation  
Circulating levels of endothelial MVs are thought to reflect a balance between cell 
stimulation, proliferation, apoptosis and other forms of cell death (136). Biological 
factors that are pertinent to vascular health and hemostasis are involved in the 
generation of endothelial MVs (Figure 3).  Among them, inflammatory and coagulation 
factors (such as TNF-D and other inflammatory cytokines, bacterial lipopolysaccharides 
(LPS), reactive oxygen species, Plasminogen Activator Inhibitor, thrombin, 
Camptothecin, C-Reactive Protein and uremic toxins, estrogens) are able to induce in 
vitro endothelial MV generation (66, 136, 141-145). Interestingly, endogenous nitric 
oxide and oxidized lipids (146) also impact on MV generation by cultured cells. Although 
little is known on the precise mechanisms involved in endothelial MVs release in vivo, 
the role of arterial shear stress has recently been demonstrated (68, 147). Generation of 
endothelial MVs from the endothelium may be considered a hallmark event reflecting 
the beginning of endothelial dysfunction. For instance, passive exposure to cigarette 
smoke rapidly (within 30 minutes) increases circulating EMVs in healthy subjects 
concomitantly with impaired endothelial function (148). 
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Evaluating the intracellular transcriptional events leading to endothelial MV formation 
in response to thrombin evidenced an early step involving genes linked to cytoskeleton 
re-organisation, such as Rho-kinase ROCK-II, followed by a second step mediated by TNF 
related apoptosis-inducing ligand (TRAIL)/Apo2L, a cytokine belonging to the TNF-D 
super-family (149). The transcription factor NF-ɈB was required both for the early and 
late production of endothelial MVs.   The activation of the p38 mitogen-activated protein 
kinase, as well as the activation of Rho kinase and extracellular signal-regulated protein 
kinases 1 and 2 by low shear stress were also identified as critical pathway in the 
production of endothelial MV (68, 136), thus providing a paracrine loop enhancing the 
endothelial response to inflammation (Figure 3). 
5.2 Multifaceted roles of endothelial MVs in vessel wall homeostasis  
The expression of anionic phospholipids, especially PS, able to bind and activate 
coagulation factors contributes to the procoagulant potential of endothelial MVs (137, 
150). Moreover, different agonists induce the generation of endothelial MVs expressing 
tissue factor (137, 146, 150, 151).  Interestingly, endothelial MVs bind to monocytes and 
induce tissue factor expression and activity (152). However, the limited evidence of 
endothelial MV contribution in vivo frustrates our knowledge of their role in coagulation 
and thrombosis. The thrombogenic activity of endothelial MVs has been demonstrated 
in a mouse model after exogenous injection of TF positive endothelial MV (153). 
However, selective deletion of tissue factor in endothelial cells has no effect on 
coagulation activation in a murine model of endotoxemia (154). Therefore, the 
increased levels of tissue factor positive endothelial MV detected in diseases such as 
sickle cell or sepsis (155, 156), suggests that TF positive endothelial MV may be 
selectively associated to certain disease states, and possibly to subsets of endothelial 
MVs that remain to be characterized. Interestingly, other studies have provided 
evidence that endothelial MVs can also exhibit anticoagulant and vasculo-protective 
activity: they can deliver miR-126 or thromboxane A2 to the vessel wall (157), and can 
expose EPCR and activated protein C (APC). APC positive endothelial MV display 
anticoagulant and cytoprotective properties effects on endothelial cells through the 
reduction of apoptosis (158). Moreover, endothelial MV also behave as a catalyst, 
supporting plasmin generation by plasminogen (94), which confer them fibrinolytic 
properties with a pivotal role for clot dissolution. These findings illustrate the broad 
scope of mechanisms involving endothelial MVs in haemostasis and thrombosis, and 
their potential beneficial capacity to influence the evolution of the disease (Figure 3).  
5.3 Role of endothelial MVs in inflammation.  
Inflammatory mediators enhance endothelial MV biogenesis in vitro. An increase in 
endothelial MVs is evident in many inflammatoryȂtype diseases such as atherosclerosis, 
diabetes or autoimmune conditions (Table 2). There is a direct correlation between 
endothelial MV number and IL-6, both in vivo and in vitro, implying a close relationship 
between endothelial vesiculation and classic inflammatory pathways of cytokine 
production (159, 160). Endothelial MVs may not only reflect the activation status of the 
cells but also confer further systemic activity, indicating that they are not only the 
consequence, but could also be involved in regulating inflammation. In addition, 
interaction between endothelial MV and naïve endothelial cells triggers pro-
inflammatory responses assessed by up-regulation of ICAM-1 mRNA expression and 
soluble ICAM-1 shedding from targeted cells, an effect that was no longer observed 
using endothelial MV from un-stimulated endothelial cells (159). Endothelial MVs 
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injected intravenously in mice lead to increased systemic and pulmonary levels of IL-1Ⱦ
and TNFȽ, correlating with an increase in neutrophils in the lung (161).  
5.4 Endothelial MVs, angiogenesis and vessel remodeling.  
The angiogenic effect of endothelial MVs is highly dependent on their composition. Some 
studies reported that endothelial MVs impair angiogenesis, but the underlying 
mechanism remains unclear.  The role of reactive oxygen species may be important as in 
vitro, angiogenesis impairment can be rescued with a cell permeable superoxide 
dismutase mimetic (162). Physiological and pathological concentration of endothelial 
MVs injected into LDLR-/- mice on a high fat diet inhibited angiogenesis in the heart 
with effects on endothelial nitric oxide synthase and NO generation (163). This 
inhibitory effect on tube formation was also reported by MVs from diabetic patients 
with coronary artery disease (164). Overall it would appear that endothelial MVs inhibit 
angiogenesis. However, endothelial MVs from human microvascular endothelial cells 
were shown to induce angiogenesis at low concentration, through plasmin generation, 
whereas higher concentrations have opposite effect (94). Within the atherosclerotic 
plaque, CD40L positive MV enhance endothelial proliferation, promoting in vivo 
neovessel formation and thus favoring intra-plaque hemorrhage (113). Ligation of 
endothelial CD40 with CD40L positive endothelial MVs modulate VEGF and PI3K: AKT 
activation and cell proliferation (113). Importantly, since some endothelial MVs can both 
promote or inhibit angiogenesis, appropriate animal models are required in order that 
the effects of endogenous release can be assessed. 
5.5 Conclusion  
Endothelial MVs are multifaceted biological vectors playing a role in both physiological 
and pathological conditions. Their pleiotropic roles identify them as active intercellular 
communicators potentially contributing to the regulation of vascular homeostasis. 
Dysregulation of endothelial MV biogenesis and its biological activities may be an 
surrogate marker of vascular dysfunction and as such provide potential biomarkers of 
endothelial dysfunction (Table 2). Although this prospect is challenging, a fully 
understanding of endothelial MV biogenesis and in vivo demonstration of their role in 
pathophysiology is required and will undoubtedly uncover new areas of vascular 
biology. 
 
3ODWHOHWPLFURYHVLFOHV 
Platelets are anucleated fragments released in the bloodstream from their cellular 
precursor, the megakaryocyte (165). Outnumbered in blood by RBCs only, platelets are 
recognized for their role in hemostasis and thrombosis. With their broad content in 
mediators and expression of receptors for immune regulatory functions, evidence also 
supports their contribution to immunity, inflammation and tissue repair (166, 167). 
Hence, studies reveal that vesicles released by platelets also convey an elaborate set of 
cargo and might play roles other than the support of coagulation and thrombosis, such 
as angiogenesis, cancer, cardiovascular diseases and inflammation (4, 134, 168, 169) 
(Table 2).  
As the megakaryocyte is a large cell that can undergo several rounds of DNA replication 
without cellular division, its cytoplasm is particularly rich in miRNA and other factors, 
which are transferred to platelets during proplatelet formation. Thus, albeit anucleated, 
platelet cytoplasm contains miRNA and the miRNA machinery such as Ago2 (170), 
Thrombosis and Haemostasis - TH-16-12-0943  revised 
 14 
which have been reported to be encapsulated within MVs (171). Growth factors (e.g. 
platelet-derived growth factor, transforming growth factor Ⱦ) (172), enzymes (e.g. 12-
lipoxygenase, thromboxane synthase) (98, 173), cytokines (e.g. IL-1) (174, 175), 
transcription factors (173) and even functional mitochondria (173, 176) (Figure 4) are 
found in platelet MVs, and can be efficiently internalized by other cells such as 
endothelial cells (106, 171), macrophages (55, 177), and neutrophils (173). Whereas the 
internalization process in endotheǯ
such as developmental endothelial locus-1 (Del-1) and the interaction of the receptor 
tyrosine kinase Axl with its ligand Gas6 found at the surface of MVs (55, 110), the 
internalization by neutrophils is also tightly regulated and requires 12-lipoxygenase 
activity present within MVs (173). Hence, platelet MVs are retrieved inside neutrophils 
in the joints of arthritic mice, and the ablation of the gene coding for 12-lipoxygenase 
(ALOX12) abrogates the internalization of MVs and consistently reduces inflammation.  
6.1 Regulation of platelet MV production 
In spite of their small size, approximately 3 µm in diameter, platelets contain an 
impressive membrane reservoir. The platelet plasma membrane comprises sinuous 
invaginations called the open canalicular system, which channels provide an important 
source of membrane permitting the formation of filopodia and spreading (up to 420%) 
on activation (178). Furthermore, impressively long (250 µm) membrane tendrils, called 
flow-induced protrusions, trail into the blood vessel from adherent activated platelets 
under flow conditions (179). Thus, although platelets are small, their abundance in 
blood and their important membrane content might explain how platelets represent a 
dominant source of MVs in blood in physiological conditions (49). 
Different platelet stimuli can trigger platelet activation via different signalling pathways 
leading to an increase in intracellular calcium. Studies have shown distinct potencies at 
inducing MV release, e.g. Ca2+ ionophore > thrombin > the glycoprotein VI (GPVI) agonist 
cross-linked collagen related peptide (CRP-XL) > co-stimulation with thrombin and CRP-
XL > collagen > LPS > thrombin receptor activating peptide  > adenosine di-phosphate 
(6). Mechanistically, platelet agonists induce the rise in intracellular calcium 
concentration, which in turn triggers cytoskeleton cleavage through calpain activation 
and cellular contraction and blebbing (30, 180). In addition to platelet agonists, platelet 
MV formation can also be triggered by physical stimuli (shear stress, hypoxia) or 
prolonged storage.  
6.2 Platelet MVs in physiological and pathological conditions 
A combination of cryo-electronic microscopy and flow cytometry determined that the 
blood at steady state contains approximately 107 platelet MVs exposing PS per ml, 
pointing to a constitutive production of MVs by platelets, potentially due to shear stress 
and platelet aging. However, studies suggest that instead, most of the MVs in blood in 
fact originate from megakaryocytes (4, 60, 181). Circulating MVs originating from 
megakaryocytes are distinguished from those derived from activated platelets by the 
presence of P-selectin, lysosomal associated membrane protein 1 and immunoreceptor-
based activation motif (ITAM) receptors (4, 60, 181). However, in pathological context 
during which platelets are activated, such as in rheumatic diseases (182), at least part of 
MVs in blood circulation were proven to originate from platelets (181). Whether platelet 
MVs contribute to the increased risks of cardiovascular diseases and thrombosis in 
patients with rheumatic disorders (183), however, remains to be established. 
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Platelet activation also occurs in the presence of complement components (184) 
providing a possible explanation for the high concentrations of platelet MVs in diseases 
where complement-mediated platelet activation occurs, such as paroxysmal nocturnal 
hemoglobinuria and aplastic anemia (185). This may indeed explain why therapy with 
eculizumab, a humanized monoclonal antibody acting as a terminal complement 
inhibitor, prevents thrombosis in patients with paroxysmal nocturnal hemoglobinuria 
(186). Hence, with their procoagulant potential, platelet MVs may play their part in 
venous and arterial thrombosis. Indeed, platelet MVs were demonstrated to play an 
important role in atherothrombotic process. Beyond being markers of platelet activation, 
platelet MVs in blood showed functional effects on atherothrombotic disease because 
they enhanced platelet and fibrin deposition on atherosclerotic arterial wall, promoting 
platelet adhesion, further recruitment of platelets and thrombus formation (187). 
Accordingly, elevated concentrations of platelet MVs are found in patients with acute 
coronary syndrome (188), transient ischemic attacks and strokes (189, 190), diabetes 
with atherothrombotic disease and peripheral arterial disease (191), heparin-induced 
thrombocytopenia with thrombosis (192), as well as myeloproliferative neoplasms 
(193) (Table 2). Platelet MVs also contribute to thrombosis in patients with 
hemoglobinopathies such as sickle cell disease and thalassemia (194, 195). Interestingly, 
in polytransfused patients with thalassemia major, the number of platelet MVs 
augments following splenectomy, and consistently these patients have a higher 
tendency to develop thrombosis (196). Thrombosis is also prevalent in cancer 
pathophysiology, and studies suggest that it might be due, at least in part, to platelet 
MVs (197), although the cancer cells themselves represent an important source of MVs 
(150). Hence, platelet MV levels correlate with the aggressiveness of certain neoplasias, 
a high level being predictive of a poor clinical outcome (193, 197, 198).  
Other molecules exposed in platelet MVs, in addition to phosphatidylserine, impact 
hemostasis and thrombosis. For instance, platelet MVs may bear activated protein C, a 
recognized anticoagulant protein, and thereby have a protective effect in early sepsis 
(199). While platelets were reported to express TF, studies by different investigators 
failed to detect TF in both resting and activated platelets (150, 200-202). Monocytes, 
however, are a major source of TF, which is stored in an encrypted form. It is suggested 
that monocyte-derived MVs harbor functional decrypted TF, and that the formation of 
highly thrombogenic platelet MVs and monocyte MVs hybrids might explain why TF has 
been reported on platelet MVs (150, 200-203). Hence, P-selectin harbored by platelet 
MVs targets MVs to the thrombi at site of injury, and injection of MVs containing P-
selectin improved the kinetics of fibrin formation and could normalize the bleeding time 
in a hemophilia mouse model (204, 205). Importantly, P-selectin, through binding with 
P-selectin glycoprotein ligand 1 (PSGL-1), recruited monocyte-derived MVs expressing 
TF to the thrombus, and further amplified thrombosis (204, 205).   
Whereas most studies on platelet MVs implicate the study of blood, platelet MVs are 
found in lymph and in the synovial fluid of patients with rheumatoid arthritis (175, 206, 
207), suggesting that they can reach locations outside blood vessels. While platelet MVs 
might display a local pro-inflammatory activity through their cytokine content, exposure 
of autoantigens and interactions with neutrophils (173, 175, 208), platelet MVs also 
deliver anti-inflammatory signals by the inhibition of IL-17 and IFN-gamma production 
by a particular set of regulatory T cells (209), reportedly present in rheumatoid arthritis 
(210), thereby enhancing the stability of the regulatory T cells in an inflammatory 
environment (209). It is not completely understood how platelet MVs egress the 
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vasculature, but it might implicate transportation by leukocytes and vascular 
permeability (211). Hence, in vivo studies revealed gaps in the arthritic joint vasculature 
that permitted the accumulation of synthetic submicron microspheres outside blood 
vessels, pointing to a role of permeability in the process (211).   ǡ     ǯ me, also called ǲǯ ǳ, leads to thrombocytopenia and bleeding tendencies (212).  ǯ 
display PS on the outer surface due to a gain-of-function mutation in the sensing protein 
stromal interaction molecule 1 gene or a loss-of-function mutation of the gene coding for 
the calcium channel pore-forming protein ORAI1 (213, 214). As circulating platelet MVs 
are elevated in this pathology, it suggests, however, that platelet MVs might not suffice 
to prevent bleedings in this condition (212). 
6.3 Conclusion  
Platelet MVs contain and elaborate cargo, which can be transferred to recipient cells, 
thus suggesting that platelet MVs might be implicated in development, angiogenesis, 
wound healing, tissue regeneration and repair and remodelling, as well as cancer (169, 
215-217). Continuous research on the topic and improvement of the detection methods 
will reveal the different roles that platelet MVs might play in health and diseases.  
 
/HXNRF\WHPLFURYHVLFOHV 
Leukocyte MVs have been shown to express adhesion molecules PSGL-1, CD11b, ICAM-
1) (63, 116, 218), IL-1Ⱦ (219), tissue factor (220) and complement receptor 3 (221). In 
addition to containing IL-1Ⱦǡ also carry active caspase 1 (222), an enzyme member 
of the inflammasome machinery needed to cleave proIL- ?Ⱦ   -18 into their 
bioactive secreted forms. These inflammasome containing vesicles were shown to also 
mediate apoptotic cell death. EVs released by membrane budding of leukocytes are 
present in high amounts locally in inflamed tissues, and detected in the circulation. 
Immune cell activation, massive leukocyte death or lympho-proliferative processes have 
direct effects on the abundance of leukocyte-derived MVs. One general feature of 
circulating leukocyte-derived MVs is that their numbers in the circulation vary in broad 
ranges. This can reflect the ability of the triggered immune system to alter the number of 
its immune cells very dynamically depending on the innate and adaptive activating or 
suppressing signals. In line with this, the number of leukocyte-derived MVs is 
substantially elevated in haematological malignancies (223-225), after severe trauma 
(226) and in sepsis (227, 228). In addition, levels of circulating leukocytes-derived MVs 
increase with the presence of cardiovascular risk factors and in patients with 
atherosclerotic vascular diseases (Table 2). 
As for platelets (4), accumulating evidence supports molecular and functional 
heterogeneity of leukocyte-derived MVs (221, 229, 230). However, the scale and 
significance of leukocyte-derived MV diversity is probably underestimated, warranting 
further investigation. While cluster of differentiation antigens provide crucial 
information about the cellular origin of the MVs, currently no tools to distinguish 
between activation- and apoptosis-induced leukocyte MVs are available. Whether 
externalized PS on the surface of MVs is a specific indicator of apoptotic cell origin has 
not been definitively demonstrated. 
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7.1 Regulation of leukocyte MV production 
Leukocyte activation is usually associated with increased cytoplasmic calcium levels. For 
example, the engagement of antigen-specific receptors (T cell receptor and B cell 
receptor) on lymphocytes, Fc gamma receptors on natural killer cells and mast cells, and 
cytokine and co-stimulatory receptors results in increased cytosolic calcium ion 
concentrations (231) (Figure 5). In vitro leukocyte-derived MV release can be triggered 
by the calcium ionophore A23187 (232). Calcium signaling in immune cells is crucial for 
controlling a wide array of adaptive cell responses including proliferation, 
differentiation and various effector functions (e.g. cytokine production); this list can be   ǳǳ ȋǤǤ  Ȍ         
cytosolic calcium level is a major trigger (233-235)(also discussed in section 2 of this 
article). Under pro-inflammatory conditions (e.g. during infection or autoimmune 
diseases), immune cell activation is associated with a leukocyte-derived MV release. 
Importantly, in the extracellular space, the released MVs are present in concomitance 
with soluble pro-inflammatory mediators (e.g. cytokines), and thus, they can have 
combined effects on cells (Figure 5). Indeed, T-cell derived MV-s were shown to 
synergize with TNF in inducing IL-8 expression by monocytes (236). The combined 
effects of different MVs with i) other EV subpopulations and/or ii) with soluble 
mediators are currently largely unexplored.  
7.2 Role of leukocyte MV in inflammation  
Inflammatory disease lesions are often hypoxic (232). Given that hypoxia is a known 
inducer of MV release (237), it may also contribute to the overall, pro-inflammatory 
condition-related induction of leukocyte-derived MV release. The released MVs in turn 
may amplify the inflammatory processes affecting different tissues (238). This is clearly 
exemplified during sepsis (a systemic inflammation) that leads to increased levels of 
circulating MVs released by granulocytes (227, 228). Due to their inherent heterogeneity 
overviewed recently (239), besides exerting pro-inflammatory effects on cells such as 
inducing cyclooxygenase 2, NF-ɈB  or inducible NO synthase (240-243), MVs can also 
play regulatory/anti-inflammatory roles as well (244-248).  
7.3 Evidence for leukocyte MVs in disease  
Important evidence linking presence of leukocyte-derived MVs and disease in vivo 
comes from a study in which MVs were studied in plaque and plasma of 26 patients 
undergoing carotid endarterectomy. Atherosclerotic plaques contained MVs 
predominantly released by leukocytes (macrophages, lymphocytes and granulocytes) 
while in contrast platelet-derived MVs were found in plasma of the same patients (140). 
Further evidence connecting leukocyte-derived MVs with disease is that stable statin-
treated heterozygous familial hypercholesterolemia patients were found to have 
elevated numbers of lymphocyte- and monocyte-derived MVs. In addition, circulating 
MVs positive for T lymphocyte antigen determinants have been identified as markers of 
lipid-rich atherosclerotic plaques in familial hypercholesterolemia (249) (Table 2). 
Accordingly, patients with high-grade carotid stenosis presented with high levels of 
leukocyte MVs (250) and a characteristic circulating leukocyte MV-signature containing 
lymphocytes, monocytes and activation markers (CD66b) in the systemic circulation 
reflected the formation of coronary thrombotic occlusions in patients with acute 
myocardial infarction (13), to whom monocyte MVs related to the long-term prognosis 
of cardiovascular death (251). Moreover, in a recent prospective 5-year follow-up 
randomized, controlled, multicenter study, T lymphocyte-derived circulating MVs were 
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found to be elevated in high cardiovascular risk subjects without clinical atherosclerosis 
who had a major cardiovascular event during the 5 year follow up period (252) (Table 
2). Finally, the role of leukocyte-derived MVs is further supported by the observation 
that circulating leukocyte-derived MVs are predictors of subclinical atherosclerosis 
burden in asymptomatic individuals (253) (Table 2). Altogether, these findings suggest 
that leukocyte MV shedding relates to atherosclerotic CVD progression, providing a link 
between inflammation and thrombosis.  
7.3 Lymphocyte MVs  
Apoptosis is associated with the release of MVs (254), and atherosclerotic plaques have 
been reported to be enriched in apoptotic lymphocytes (255). Hence, lymphocyte MVs 
have been detected in atherosclerotic plaques (256). Furthermore, circulating T 
lymphocyte-derived MVs are elevated in familial hypercholesterolemia patients (249). 
Thus, the link between lymphocyte derived-MVs and atherosclerosis is supported by 
numerous reports. T cell-derived MVs were shown to impair endothelial function (257). 
On the other hand, vascular hyperreactivity was also documented and lymphocyte-
derived MVs were shown to inhibit angiogenesis (258). The LDL receptor has been 
proposed to mediate the uptake of T cell-derived MVs and influence the VEGF pathway 
(259).  
Also, data suggest a link between lymphocyte-derived MVs and preeclampsia. In 
preeclamptic women T cell- and granulocyte-derived MVs were increased compared 
with normal pregnancy (235). Furthermore, synovial fluid CD8+ T cell-derived MV 
profiles were found to be characteristic for rheumatoid arthritis (206) suggesting that 
leukocyte MVs may potentially hint at locally activated immune cell populations.  
Surprisingly, there are very few reports published on circulating B cell-derived MVs, 
mainly related to B cell malignancies (224, 260-262). 
7.5 Conclusion  
MVs derived from leukocytes can play effector roles in the pathophysiological 
mechanisms of different diseases. Recent advances in immunology have identified high 
number of immune cell subsets. From the MV research perspective, MVs secreted by 
these immune cell subsets, represent a highly promising, however, yet minimally 
explored area of research that deserves further attention. 
 
5HGEORRGFHOOPLFURYHVLFOHV 
RBCs are 700,000 to 5.2 million to a microliter of blood. Any stimulus of RBC 
vesiculation, such as calcium influx and spicule extension (263-270), may thus trigger a 
significant storm of RBC-derived MVs (271).  Indeed, RBC MVs are amongst the most 
common circulating vesicles, and they are particularly elevated during intravascular 
hemolysis, in ST-segment elevation myocardial infarction (272, 273) related to 
myocardial damage (273), in sickle cell disease (50, 274-277), thalassemia (277-279) 
and during blood pocket storage and aging (280-283), among others. RBCs are also 
thought to release MVs spontaneously during reticulocyte maturation (284) and upon 
plasmodium falciparum replication (285). 
RBC-derived MVs display many characteristics and activities common to other MVs, 
including externalization of PS, with subsequent pro-coagulant effects (50, 279, 286-
288), complement pathway activation (289) and a pro-inflammatory impact on blood 
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vessels (290). RBC-derived MVs, like their mother cells, are also unique due to the 
quantity of iron that they carry. Each RBC contains about 250 million molecules of 
hemoglobin, each with 4 prosthetic haeme groups and 4 iron ions. Leakage of 
hemoglobin out of only 0.1% RBC results in an increase up to 2 µM in plasma 
hemoglobin. These significant concentrations of hemoglobin attracted attention with 
respect to vesiculation during intravascular hemolysis.  
One relevant question relates to the retention of hemoglobin, haeme and iron by MVs 
during RBC vesiculation and hemolysis. MV depletion experiments using differential 
centrifugation or size fractionation of plasma suggest that 5% to 40% of extracellular 
hemoglobin associates with RBC membrane fragments during sickle cell disease (291), 
thalassemia (279) and blood aging (281). Hemolysis, as defined today, is thus likely to 
comprise vesiculation as a mode of hemoglobin exit from RBC and a mode of 
presentation in plasma, beyond haeme association with classical partners such as 
hemopexin, haptoglobin, albumin and LDL.  
A second question pertains to the redox state of MV-contained hemoglobin, haeme and 
iron. The pseudoperoxidase activity of these molecules is linked to the level of enzymatic 
control applied by porphyrins and globins onto the iron atoms. This may prove critical 
to the pathophysiological impact of RBC-derived MV. Healthy MVs may contain mostly 
intact hemoglobin, like inert RBCs. Pathological RBC MVs may contain excess haeme and 
trigger radical oxygen species production by vascular endothelial cells through TLR-4 
signaling, like in sickle cell disease (291, 292).  
Early biochemical analyses suggested that hemoglobin remains functional and able to 
exchange gases, judging by the NO-depleting and vaso-constrictive effects of RBC MV 
(281, 283, 291, 293). RBC MVs may contain a significant proportion of meth-hemoglobin 
(291), an oxidized metabolite prone to releasing free haeme. When RBC vesiculation is 
coupled to hemoglobin injury, MV may transport lipophilic, protein-free haeme (Figure 
6). This association would prove deleterious, as haeme embedded into membrane 
phospholipids is known to release iron and catalyze extensive oxidative degradation of 
nearby lipids and proteins. RBC MVs may thus sequester haeme away from classical 
recycling pathways, and mediate unique effects through a mixed load of haeme and lipid 
metabolites.  
 
/LPLWDWLRQVDQGIXWXUHGLUHFWLRQV 
During their formation process, MVs retain functional receptors, proteins, bioactive 
lipids, organelles and genetic material from the parental cells, and behave as active 
sensors, communicators, and effectors on their surrounding environment. There are a 
number of important points that need to be considered when designed and analysing 
experiments to investigate the presence and function of MVs: 
x Numerous pitfalls could occur during their isolation procedure and their 
characterization, such as the presence of contaminating protein. Therefore, one 
should rely on at least two different technical approaches to identify them, with 
consideration given to the limitations of each approach. We should also bear in 
mind that pharmacological interventions in patients can modulate MV circulating 
levels, either directly or indirectly.  
x As highlighted in this review, there is an emerging role for MVs in vascular 
homeostasis and disease. However, further research is needed to pin down the 
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molecular mechanisms involved to further elucidate MVs potential as therapeutic 
targets or vectors. 
x To accelerate the progress with biomarker discovery, we need to enhance our 
understanding of the biological role played by specific cell derived MVs in 
haemostasis. For example, understanding the role of EMVs in vascular     ǯ  
be interpreted in a more meaningful manner.  
x MVs, and more generally extracellular vesicles, are becoming an intense area of 
research as therapeutic targets in heart diseases. In addition, improved 
characterisation of their content and surface molecule expression will aid in 
integrating information regarding their function in normal physiology with their 
pathological role.  
Central to the above is the optimisation and standardisation of isolation and analysis of 
MVs and the use of robust experimental controls. 
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Table 1: Measuring the efficiency of MV isolation procedures. 
Starting material, for example plasma or conditioned cell culture medium, will contain 
MVs, proteins and lipoproteins. To determine the recovery of MVs, measure MVs before 
(starting material) and after isolation, and express the recovery as [concentration 
isolated MV]/[concentration MVs in starting material] x 100%. Confirm the identity of 
MVs in obtained fraction(s) by electron microscopy. Finally, to determine the (relative) 
enrichment of isolated MVs compared to the starting material, measure the 
concentration of protein and lipoprotein before and after isolation, and calculate the 
ratio of [MV concentration]/[protein concentration] and [MV 
concentration]/[lipoprotein concentration].  
*MVs cannot be visualized directly in most fluids due to the presence of proteins and 
other contaminants. 
 
  Starting material Isolated MV 
Recovery MV Measure MV + + 
Confirm MV identity Electron Microscopy N/A* + 
Contamination Measure protein 
Measure lipoprotein 
+ 
+ 
+ 
+ 
Enrichment of MV EV/protein ratio 
EV/lipoprotein ratio 
+ 
+ 
+ 
+ 
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Table 2 : Plasma MV changes in subjects with cardiovascular risk factors and in patients with 
atherosclerotic vascular diseases. CVD: cardiovascular diseases; TF: tissue factor; PS+ MVs: MVs 
expressing phosphatidylserine; ND : Not determined.  
 
 MV sub-population changes references 
C
a
r
d
io
v
a
s
c
u
la
r
 r
is
k
 f
a
c
to
r
s 
Age Endothelial, TF+MV, 
PS+MV 
Ï,Ð (294, 295) 
Female gender Endothelial, Platelet, 
PS+MV 
Ï (296) 
Hypertension Endothelial, platelet Ï (297, 298)  
Hypercholesterolemia Endothelial, lymphocyte, 
leucocyte, platelet 
Ï (249, 299) 
Hypertriglyceridemia Endothelial Ï (298, 300) 
Smoking, Pollution Endothelial, platelet, 
leucocyte 
Ï (148, 301-
303) 
Obesity Endothelial, platelet Ï (304-307) 
Diabetes Endothelial, platelet, 
leucocyte, TF+MV 
Ï (308-310) 
Metabolic syndrome Endothelial Ï (298, 311) 
Family history CVD ND ND ND 
Physical inactivity Endothelial Ï (312) 
A
th
e
r
o
s
c
le
r
o
ti
c
 v
a
sc
u
la
r
 
d
is
e
a
se
s
 
 
Subclinical atherosclerosis Leucocyte, platelet, 
lymphocyte, endothelial 
Ï (249, 253, 
299, 313) 
Coronary calcification Endothelial, Platelet Ï (314) 
Acute coronary syndrome Endothelial, Platelet, 
monocyte 
Ï (13, 310, 315-
319) 
Stable coronary disease Endothelial, Platelet Ï (316, 320) 
Cardiac sudden death Endothelial Ï (321) 
Acute stroke Endothelial, platelet, 
leukocyte 
Ï or no 
change 
(189, 322-
324)  
Cerebrovascular atherosclerosis Endothelial Ï (325) 
Peripheral artery disease Platelet  Ï (326-328)  
End-stage renal disease Endothelial, platelet , 
erythrocyte 
Ï  (329, 330) 
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Figure 1: Floppase activity and facilitated transport of phosphatidylserine by 
TMEM-16 F (ANO-6) and procoagulant MV shedding.  
At rest, phosphatidylserine (PS) is translocated to the inner leaflet by flippase activity. 
Right panel: Upon cell activation and calcium-dependent flippase inhibition, PS 
translocation to the outer leaflet is driven by TMEM-16F (yellow shape) and local K+ 
efflux prompts cell shrinkage and re-shaping. High calcium concentration promoted by 
Stored Operated Channels (SOCE) favours the constitution of TMEM16-F platforms by 
oligomerization or interaction with other receptors like P2XR in the case of long term 
exposure to Ca2+ (green shape). Transient phospholipid imbalance between leaflets and 
the proteolysis of cytoskeleton by calpains and/or caspases lead to facilitated 
procoagulant MV shedding. Putative scramblase transducers as Xkr8 are activated by 
caspases and would trigger enhanced floppase activity as described in apoptotic cells 
(see text for details). Exposed PS catalyses the assembly of blood coagulation complexes 
at cell and MV surface (E: Enzyme, S: Substrate, CF cofactor)   
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Figure 2: Molecular component and pathways used by MVs to regulate cell 
communication. MVs may transfer membrane components and cytosolic and nucleic 
acids to the target cell by internalization or following membrane fusion. MVs 
interactions with membrane-associated receptors may induce specific responses in 
target cells. Uptake of some mediators, such as miRNA, induces reprogramming of target 
cells. Receptors present on MV surface could be recycled and presented on the surface of 
the target cell. 
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Figure 3:  Biogenesis and biological effects of endothelial MVs. Endothelial MV 
release can be triggered following cell activation or apoptosis. The resulting remote 
biological effects of endothelial MVs can be either protective or deleterious.  TNFD = 
Tumor necrosis factor alpha; LPS = lipopolysaccharide; ROS = reactive oxygen species; 
PAI-1 = plasminogen activator inhibitor-1; CRP = C-reactive protein; AngII = angiotensin 
II; oxLDL= oxidized-low density lipoprotein; ROCK-1 or -2 = Rho associated protein 
kinase 1 or 2; NF-ɈB= nuclear factor kappa-b, TRAIL/Apo2L= TNF-related apoptosis 
inducing ligand; p38 MAPK= p38 mitogen-activated protein kinase; ERK 1/2 = 
extracellular signal-regulated kinases. 
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Figure 4: Composition of platelet-derived MVs 
Platelet MVs are produced by activated platelets on disruption of membrane asymmetry 
and plasma membrane budding (steps 1 and 2). Although platelets are anucleated, they 
do contain a broad arsenal of molecules, which can be transferred to platelet MVs. 
Adapted from Melki et al. Platelets 2016. 
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Figure 5: Leukocyte MV formation. MV release by leukocytes is triggered by i) 
engagement of various cell surface receptors by activating ligands that lead to increased 
cytosolic calcium ion concentration as well as ii) by hypoxic environment. MVs and 
conventional mediators (cytokines) are present simultaneously in the extracellular 
space and may exert combinatorial effects on cells. A few pathological conditions with 
confirmed role of leukocyte-derived MVs are listed. TCR = T cell receptor; BCR = B cell 
receptor ; NK = natural killer cell. 
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Figure 6: Red blood cell MVs are unique transporters of haeme.   
Red blood cell (RBC) release MVs under stress, probably from membrane buds called 
spicules. RBC MVs contain high amounts of haemoglobin originating from their parent 
cell cytoplasm. RBC MVs may thus transport unusually high amounts of haeme and iron, 
bringing these highly pro-oxidant molecules in close proximity of their target cell 
membranes, with a vast array of possible pathophysiological consequences, which 
remain to be explored.  
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